Search results
Results from the WOW.Com Content Network
(Reuters) -FibroGen Inc said on Monday it is regaining rights to the anemia drug, roxadustat, from AstraZeneca in the United States and certain other territories after the companies agreed to ...
BBC News provides television journalism to BBC network bulletins (on BBC One and BBC Two) and programmes as well as the BBC News Channel available around the world and in the United Kingdom. BBC News runs BBC Radio 5 Live and BBC World Service as part of its rolling news coverage, journalists and presenters also contribute to podcasts produced ...
One thing we could say about the analysts on FibroGen, Inc. ( NASDAQ:FGEN ) - they aren't optimistic, having just made... News Flash: 10 Analysts Think FibroGen, Inc. (NASDAQ:FGEN) Earnings Are ...
Get breaking news and the latest headlines on business, entertainment, politics, world news, tech, sports, videos and much more from AOL
BBC Sportsday – All the latest sports news and results from around the globe. Sunday with Laura Kuenssberg – Interviews and analysis of the weeks big news from the UK and around the world stories, including interviews with key politicians and personalities from all walks of life. Business Today – The latest business news. Launched on 7 ...
Business Today is a television business news programme produced by BBC News and shown on BBC News Channel and BBC One on weekdays. Each edition lasts 25 minutes. The 05:30 edition is also seen on BBC One and the 11:30 edition also airs on BBC Two during their simulcasts of BBC News Channel.
This is an accepted version of this page This is the latest accepted revision, reviewed on 19 December 2024. English-language pay television channel This article is about the English-language audio-visual international news and current affairs operations of the BBC. For the BBC's corporate division administering it, as well as the audio-only branding of the same, see BBC World Service. This ...
Novo Nordisk’s latest attempt in weight loss, a combination drug called CagriSema, matched the bar set by Lilly’s currently approved medicine, Zepbound, but didn’t cleanly surpass it in late ...